Inflammatory Diseases Archives - Xtalks

Wednesday, August 12, 2026 | 11am EDT: Accelerate Cell Culture Media Development with Automated Cell Analysis

Tozorakimab Scores Double Win in Phase III COPD Trials

J&J’s Icotyde (Icotrokinra) Receives FDA Nod as First Oral Biologic for Plaque Psoriasis

Advancing Complement-Targeted Therapies from Bench to Bedside

Evommune $150M IPO to Further Innovation for Chronic Inflammatory Diseases

November 7, 2025

Inside the Curanex Pharmaceuticals IPO: Botanical Therapies for Ulcerative Colitis and More

September 4, 2025

Psoriasis Awareness Month 2025: Advancing Research, Treatment and Understanding

J&J’s Icotrokinra Shows Clear Skin Outcomes in Phase III

FDA Approves Gamifant (Emapalumab), First Therapy for Macrophage Activation Syndrome in Still’s Disease

CSL’s Andembry (Garadacimab) Gets FDA Approval as New HAE Prophylactic Option

Starjemza (Ustekinumab) FDA Approval: 2025’s First Biosimilar for Stelara in Psoriasis Care

Apimeds Pharmaceuticals US IPO Backs Bee Venom for Osteoarthritis Treatment

Life Science Podcast

Innovating Treg Therapies for ALS and Alzheimer’s with Coya Therapeutics CEO Dr. Arun Swaminathan — Episode 200

Eli Lilly’s Omvoh Wins Second FDA Approval, Expanding Use to Crohn’s Disease

January 21, 2025

Clinical Trial News

Cenerimod Reduces SLE Disease Activity, Paves the Way for Phase III

December 30, 2024

First Stelara Biosimilar, Wezlana, Gets FDA Nod for Crohn’s, UC, Psoriasis but Faces Delayed Launch

November 2, 2023